Core Viewpoint - The company announced that its joint venture, Yangzhou Shizhiyuan Biotechnology Co., Ltd., has recently been granted a patent by the National Intellectual Property Administration for an invention related to monoclonal antibodies targeting CD4, aimed at preventing, treating, and functionally curing HIV infections [1] Group 1 - The patent is specifically for a method involving monoclonal antibodies against CD4, their compositions, and the use of these compositions in the context of HIV infection [1] - This development represents a significant advancement in the treatment and potential functional cure for HIV, highlighting the company's innovative capabilities in biotechnology [1]

人民财讯12月19日电，申联生物(688098)12月19日公告，联营公司世之源于近日获得国家知识产权局颁 发的"藉由针对CD4之单克隆抗体介导竞争型HIV进入抑制之HIV感染的治疗和功能性治愈"的发明专 利，此发明专利是关于针对CD4单克隆抗体、其组合物以及使用此组合物以预防、治疗和功能性治愈 HIV感染的方法。 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 12月19日，申联生物收涨2.15%，收盘价为9.01元，发生1笔大宗交易，合计成交量205.3万股，成交金 额1806.64万元。 责任编辑：小浪快报 第1笔成交价格为8.80元，成交205.30万股，成交金额1,806.64万元，溢价率为-2.33%，买方营业部为中 信建投证券股份有限公司广西分公司，卖方营业部为国信证券股份有限公司上海陆家嘴环路证券营业 部。 进一步统计，近3个月内该股累计发生1笔大宗交易，合计成交金额为1806.64万元。该股近5个交易日累 计上涨0.67%，主力资金合计净流出240.99万元。 ...

Core Insights - The animal health sector experienced a slight increase of 0.42% on December 19, with Huisheng Biological leading the gains [1] - The Shanghai Composite Index closed at 3890.45, up 0.36%, while the Shenzhen Component Index closed at 13140.22, up 0.66% [1] Stock Performance - Huisheng Biological (300871) closed at 20.75, with a rise of 2.47% and a trading volume of 45,200 shares, amounting to a transaction value of 92.96 million yuan [1] - Other notable performers included: - Qudongli (920275) at 9.27, up 2.43% [1] - Shenlian Biological (688098) at 9.01, up 2.15% [1] - Xianfeng Holdings (002141) at 3.74, up 1.91% [1] - Ruipu Biological (300119) at 19.60, up 1.87% [1] Capital Flow - The animal health sector saw a net outflow of 129 million yuan from institutional investors, while retail investors contributed a net inflow of 157 million yuan [2][3] - The detailed capital flow for selected stocks showed: - Xianfeng Holdings (002141) had a net inflow of 6.89 million yuan from institutional investors [3] - Ruipu Biological (300119) experienced a net outflow of 15.98 million yuan from institutional investors but a net inflow of 11.27 million yuan from retail investors [3] - Qudongli (920275) had a net inflow of 2.22 million yuan from retail investors [3]

Core Insights - The animal health sector experienced a decline of 0.31% on December 10, with *ST Lvkang leading the drop [1] - The Shanghai Composite Index closed at 3900.5, down 0.23%, while the Shenzhen Component Index rose by 0.29% to 13316.42 [1] Stock Performance - The following stocks in the animal health sector showed varied performance: - **Biological Shares (600201)**: Closed at 14.53, up 1.18% with a trading volume of 395,300 shares and a turnover of 560 million yuan [1] - **Ruipu Biological (300119)**: Closed at 19.24, up 0.79% with a trading volume of 26,900 shares and a turnover of 51.56 million yuan [1] - **Xianfeng Holdings (002141)**: Closed at 3.82, up 0.53% with a trading volume of 177,700 shares and a turnover of 67.70 million yuan [1] - **Qudongli (920275)**: Closed at 8.71, up 0.23% with a trading volume of 9,815 shares and a turnover of 8.47 million yuan [1] - **Jinhe Biological (002688)**: Closed at 6.05, down 0.17% with a trading volume of 67,700 shares and a turnover of 40.90 million yuan [1] - **Hui Sheng Biological (300871)**: Closed at 19.24, down 0.52% with a trading volume of 23,700 shares and a turnover of 45.48 million yuan [1] - **Dayu Biological (920970)**: Closed at 7.70, down 0.65% with a trading volume of 11,700 shares and a turnover of 892,880 yuan [1] - **KQ Biological (688526)**: Closed at 15.36, down 0.65% with a trading volume of 17,600 shares and a turnover of 26.94 million yuan [1] - **Placo (603566)**: Closed at 12.95, down 0.69% with a trading volume of 27,200 shares and a turnover of 35.32 million yuan [1] - **Shenlian Biological (688098)**: Closed at 8.96, down 1.10% with a trading volume of 31,800 shares and a turnover of 28.66 million yuan [1] Capital Flow - On the same day, the animal health sector saw a net outflow of 13.98 million yuan from institutional investors and 18.34 million yuan from retail investors, while individual investors contributed a net inflow of 32.32 million yuan [3]

Core Insights - The animal health sector experienced a rise of 1.81% on December 8, with BioShares leading the gains [1] - The Shanghai Composite Index closed at 3924.08, up 0.54%, while the Shenzhen Component Index closed at 13329.99, up 1.39% [1] Stock Performance - BioShares (600201) closed at 14.39, with a significant increase of 7.39% and a trading volume of 717,500 shares, amounting to a turnover of 1.014 billion yuan [1] - Other notable stocks included: - Zhongmu Co. (600195) at 8.09, up 1.25% [1] - Deyu Bio (920970) at 7.88, up 0.90% [1] - Yongshun Bio (920729) at 8.85, up 0.80% [1] - Ruipu Bio (300119) at 19.37, up 0.73% [1] Capital Flow Analysis - The animal health sector saw a net outflow of 27.984 million yuan from institutional investors, while retail investors contributed a net inflow of 4.809 million yuan [2] - The main capital flow for BioShares (600201) showed a net inflow of 26.5384 million yuan from institutional investors, despite a net outflow of 35.9123 million yuan from retail investors [3] - Other stocks like *ST Lvkang (002868) and Huisheng Bio (300871) also experienced varied capital flows, with institutional and retail investors showing different trends [3]

Core Viewpoint - The animal health sector experienced a decline of 0.7% on December 2, with Shenyuan Biological leading the drop. The Shanghai Composite Index closed at 3897.71, down 0.42%, while the Shenzhen Component Index closed at 13056.7, down 0.68% [1][2]. Stock Performance Summary - The closing prices and performance of key stocks in the animal health sector are as follows: - Shenyuan Biological (688088) closed at 9.28, down 2.93% with a trading volume of 40,900 shares and a turnover of 38.24 million yuan [2]. - Shengong Holdings (002141) closed at 4.13, down 0.96% with a trading volume of 387,200 shares and a turnover of 159 million yuan [1]. - Other notable stocks include: - Biological Shares (600201) at 12.45, up 1.63% [1]. - Zhongmu Shares (600195) at 7.64, down 0.26% [1]. - Jinhai Biological (002688) at 6.17, down 0.32% [1]. Capital Flow Analysis - The animal health sector saw a net outflow of 10.78 million yuan from institutional investors, while retail investors had a net inflow of 16.68 million yuan [2][3]. - Key capital flow details include: - Shengong Holdings had a net inflow of 8.69 million yuan from institutional investors [3]. - ST Green Kang (002868) experienced a net inflow of 5.73 million yuan from institutional investors [3]. - Other stocks like Hailey Biological (603718) and Jinhai Biological (002688) showed mixed capital flows with varying net inflows and outflows [3].

Core Viewpoint - The animal health sector experienced a decline of 0.48% on December 1, with *ST Lvkang leading the drop, while the overall market indices showed positive performance with the Shanghai Composite Index rising by 0.65% and the Shenzhen Component Index increasing by 1.25% [1][2]. Market Performance - The closing price of *ST Lvkang was 39.35, reflecting a decrease of 3.41% with a trading volume of 30,400 shares and a transaction value of 122 million yuan [2]. - Other notable stocks in the animal health sector included: - Dayu Biological: Closing price 8.26, up 2.10% [1] - Haili Biological: Closing price 6.86, up 1.03% [1] - Qihua Biological: Closing price 15.85, up 0.51% [1] - Repu Biological: Closing price 19.83, down 0.10% [1][2]. Capital Flow - The animal health sector saw a net outflow of 29.57 million yuan from institutional investors, while retail investors contributed a net inflow of 3.27 million yuan [2][3]. - Specific stock capital flows included: - Jinhai Biological: Net inflow from institutional investors of 3.13 million yuan [3]. - Haili Biological: Net inflow from institutional investors of 2.06 million yuan [3]. - Repu Biological: Net inflow from retail investors of 2.81 million yuan [3].

证券代码：688098 证券简称：申联生物 公告编号：2025-040 一、本次解除冻结的股份原冻结情况 股东 UBI 所持公司 1,815,221 股股份存在被司法冻结的情形，内容详见公司 于 2019 年 12 月 5 日在上海证券交易所网站（www.sse.com.cn）披露的《申联生 物医药(上海)股份有限公司关于持股 5%以上股东股份被司法冻结的公告》（公 告编号：2019-008）。 股东 UBI 被法院强制执行被动减持公司股份 730,000 股，内容详见公司于 2023 年 3 月 23 日在上海证券交易所网站（www.sse.com.cn）披露的《申联生物 医药(上海)股份有限公司持股 5%以上股东部分股份被动减持的公告》（公告编 号：2023-004）。2023 年 3 月 30 日，股东 UBI 被法院强制执行被动减持公司股 份 4,000 股作为前述事项执行费，因此 UBI 持有的公司股份冻结数量为 1,081,221 股。 申联生物医药(上海)股份有限公司 关于持股 5%以上股东所持股份解除冻结的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏， ...

申联生物医药（上海）股份有限公司 简式权益变动报告书 证券代码：688098 证券简称：申联生物 申联生物医药（上海）股份有限公司 简式权益变动报告书 上市公司：申联生物医药（上海）股份有限公司 股票上市地：上海证券交易所 股票简称：申联生物 股票代码：688098 信息披露义务人：UNITED BIOMEDICAL,INC. 住所：25 Davids Drive Hauppauge, NY 11788, USA 通讯地址：25 Davids Drive Hauppauge, NY 11788, USA 股份变动性质：股份减少 签署日期：2025 年 11 月 28 日 申联生物医药（上海）股份有限公司 简式权益变动报告书 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司收购管理办法》（以下简称"《收购办法》"）、《公开发行证券的公 司信息披露内容与格式准则第 15 号—权益变动报告书》（以下简称"《准则 15 号》"）及相关的法律、法规编写本报告书。 二、信息披露义务人签署本报告已获得必要的授权和批准，其履行亦不违反 信息披露义务人章程或内部规则中的 ...